China's National Medical Products Administration accepted the application of Beijing Centergate Technologies Holding's (SHE:000931) subsidiary, Beijing Huasu Pharmaceutical, to market extended-release oxycodone hydrochloride tablets, according to a Shenzhen Stock Exchange disclosure on Thursday.
The drug is used for the treatment of severe pain that requires long-term, continuous use of opioids, and when substitution therapies are not adequate to relieve the pain, the Chinese biomedicine and healthcare company said.
The company's shares closed 2% higher.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.